Mirati Therapeutics Reports Third Quarter 2022 Financial Results ...

The Company expects to provide topline results from the interim analysis of the global, registration-enabling Phase 3 SAPPHIRE study evaluating ...

Mirati Therapeutics to Report Third Quarter 2022 Financial Results ...

Mirati Therapeutics (NASDAQ: MRTX) will announce its third-quarter financial results and corporate updates on November 8, 2022, at 4:30 p.m. ET.

Mirati Therapeutics Reports Third Quarter 2023 Financial Results ...

License and collaboration revenue for the same periods in 2022 was $5.4 million and $11.5 million, respectively, related to milestone payments ...

Mirati Therapeutics to Report Third Quarter 2022 Financial Results ...

SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. , a clinical-stage targeted oncology company, will announce financial ...

Mirati Therapeutics Reports Third Quarter 2022 Financial Results ...

Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates. 2 years ago$MRTXEarnings DateHealth CarePRNewswire PR. We ...

Mirati Therapeutics Inc (MRTX) Reports Q3 2023 Financial Results

Mirati Therapeutics Inc (NASDAQ:MRTX) announced its Q3 2023 financial results, highlighting a net KRAZATI product revenue of $16.4 million.

Investor relations - Bristol Myers Squibb

10/31/2024. Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 ... Mirati shareholders. Frequently asked questions about Mirati. Learn More.

Document - SEC.gov

The Company published the 2022 Corporate Sustainability Report, the Company's second annual report, which provides information describing investments and ...

MIRA TI THERAPEUTICS 2022 ANNU AL REPOR T

... Mirati Therapeutics, Inc. Opinion on Internal Control Over Financial Reporting ... Baum (incorporated by reference to Mirati Therapeutics Inc.'s Quarterly Report ...

Quarterly Results | Marker Therapeutics, Inc.

Quarterly Results ... Show all ... 2024 ... Second Quarter ... First Quarter ... 2023 ... Fourth Quarter ... Third Quarter ... Second Quarter ... First Quarter ... 2022 ... Fourth ...

Kura Oncology Reports Third Quarter 2023 Financial Results

Research and development expenses for the third quarter of 2023 were $29.3 million , compared to $25.0 million for the third quarter of 2022. General and ...

Zai Lab Announces Third Quarter 2022 Financial Results and ...

Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates · Regional strategic collaboration for TIVDAK® (tisotumab vedotin) strengthens Zai ...

Revolution Medicines Reports Third Quarter 2022 Financial Results ...

“Finally, in July 2022, we completed a public equity financing raising gross proceeds of approximately $265 million that strengthened our ...

Incyte Reports 2023 Third Quarter Financial Results and Provides ...

Net product revenues of $92 million grew 141% compared with the third quarter of 2022, driven by growth in patient demand, refills and expansion in payer ...

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial ...

Results Reflect Continued Strength of In-Line and New Products, Pipeline Execution and Business Development Activity, Supporting Growth ...

MRTX SEC Filings - Mirati Therapeutics, Inc.- Annual Report, Proxy ...

Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates SAN DIEGO ? November 8, 2022 ? Mirati Therapeutics, Inc. 2022 ...

Mirati Therapeutics Reports Second Quarter 2023 Financial Results ...

There was no cost of product revenue for the same periods in 2022. Research and development expenses for three and six months ended June 30, ...

Document - SEC.gov

Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates ... third line non-squamous NSCLC. The Company expects to ...

Mirati Therapeutics Stock News (MRTX) - Page 5 - Public.com

Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates. PRNewsWire • 11/08/22. Mirati Therapeutics Appoints Alan ...

Zai Lab Announces Third Quarter 2023 Financial Results and ...

Product revenues were $69.2 million for the third quarter of 2023, compared to $57.0 million for the same period in 2022, representing 22% yoy growth and 27% ...